|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||72.07 - 73.11|
|52 Week Range||67.53 - 95.93|
|PE Ratio (TTM)||43.25|
|Earnings Date||Nov 7, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||0.76 (1.03%)|
|1y Target Est||81.23|
Haeggquist & Eck, LLP, a leading shareholder rights litigation firm, is investigating whether directors and officers of Perrigo Company plc (“Perrigo”) (PRGO) breached their fiduciary duties to Perrigo and its shareholders. If you are a Perrigo shareholder, you are encouraged to contact Amber Eck at Haeggquist & Eck for additional information. Perrigo, together with its subsidiaries, develops, manufactures, markets, and distributes over-the-counter consumer goods and pharmaceutical products worldwide.
Today I will be providing a simple run through of a valuation method used to estimate the attractiveness of Perrigo Company plc (NYSE:PRGO) as an investment opportunity by projecting itsRead More...
Perrigo (PRGO) announces approval of over-the-counter equivalent of Imodium Multi-Symptom Relief tablet in the United States.
TASE: PRGO) today announced that it has received final approval from the U.S. Food & Drug administration for the store brand over-the-counter (OTC) equivalent of Imodium® Multi-Symptom Relief (loperamide hydrochloride and simethicone tablets, 2 mg/125 mg). This product will be packaged and marketed as store brands or retailer 'own label' brands and will provide consumers with a high-quality, value alternative to the national brand. Perrigo is finalizing plans to launch its wholly owned store brand loperamide hydrochloride and simethicone tablets, 2 mg/125 mg, in the fourth quarter of 2018.
TASE: PRGO) today announced that it has postponed its investor event to discuss its long-term consumer growth strategies and key operational initiatives, previously planned as a conference call for September 25, 2018. The Company will provide an update on timing at a later date for an in-person investor meeting to communicate these important strategies and initiatives to drive long-term growth. Perrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Affordable Healthcare Products®.
This article is intended for those of you who are at the beginning of your investing journey and want to start learning about core concepts of fundamental analysis on practicalRead More...
The Dow Jones Industrial Average jumped 0.35 percent to close at 25,758.69, while the S&P 500 Index have gained 0.24 percent to close at 2,857.05. The Nasdaq Composite Index increased 0.06 percent to close at 7,821.01.
NEW YORK, NY / ACCESSWIRE / August 20, 2018 / U.S. equities continued to rally in Friday as hopes of easing trade tensions between the U.S. and China outweighed recent concerns of the currency crisis in ...
Perrigo Company PLC, (NYSE: PRGO ) was hit with a downgrade from Deutsche Bank after an eventful week that included the announced separation of its prescription pharmaceutical business and its second-quarter ...
Perrigo Co. plans to shed its prescription pharmaceutical unit, which accounts for about one-fifth of total revenue, following a strategic review of its portfolio. Perrigo, which makes private-label products such as cold medicines and infant formula, said Thursday its board believes the separation would create shareholder value and allow the company to focus on expanding its consumer business. Perrigo said it plans to complete the separation in the second half of 2019.
Moody's Investors Service ("Moody's") commented that Perrigo Company plc's ("Perrigo") Baa3 senior unsecured rating and stable outlook are not immediately impacted by its announcement on August 9, 2017, that the company plans to separate its Prescription Pharmaceutical business ("Rx business"). For additional information please refer to Moody's Issuer Comment on Perrigo Company plc available on www.moodys.com.
Shares of Mylan (MYL) and Perrigo (PRGO) are falling on Thursday after the drugmakers revised their full-year outlooks lower. Where we were: While health-care and pharmaceutical stocks have outperformed the broader market, both Perrigo and Mylan have been left out of the party, falling 19.1% and 12.7%, respectively, year to date. The second-quarter earnings season has been quite strong, but it's been a tough couple of days for specialty pharmaceutical companies.
Generic drugmakers such as Perrigo, Mylan (MYL.O) and Teva Pharmaceutical Industries (TEVA.TA) have suffered over the past few years as price erosion has pressured their bottom lines. "The company (Perrigo) has been actively discussing this potential separation for some time and the lack of a buyer thus far to us suggests this won't be easy," RBC Capital Markets analyst Randall Stanicky said. Perrigo's announcement comes just a day after larger rival Mylan said it was evaluating all strategic options, citing a tough U.S. environment for generic drugmakers.
Perrigo Co. PLC (PRGO) shares dropped 6.5% in Thursday premarket trade after the Ireland-based generic drugmaker reported a second-quarter revenue miss and made cuts to its 2018 guidance. Perrigo said weakness in its prescription drug business drove the results, and separately announced plans to parcel out the unit -- which sells various topical generic products -- from its consumer business. The company is considering options like a business separation, sale or merger, which would likely take place in the second half of next year.
Check out the companies making headlines before the bell: Viacom VIAB – The media company reported adjusted quarterly profit of $1.18 per share , 11 cents a share above estimates. Revenue was essentially in line with forecasts, but was down about 3.
Perrigo (PRGO) delivered earnings and revenue surprises of 0.83% and -3.48%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Perrigo Co. Plc (NYSE: PRGO ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 8:30 AM Eastern Time. To listen ...
On a per-share basis, the Dublin-based company said it had profit of 26 cents. Earnings, adjusted for one-time gains and costs, came to $1.22 per share. The results surpassed Wall Street expectations. ...
TASE: PRGO) announced today that it has entered into a licensing agreement with a subsidiary of Merck & Co, Inc., Kenilworth, NJ, USA for the exclusive rights in the United States to pursue regulatory approval for a non-prescription, over-the-counter ("OTC") Nasonex® (mometasone furoate monohydrate) Nasal Spray. Under the terms of the agreement, Perrigo holds exclusive rights to market, sell, and distribute a non-prescription version of Nasonex® OTC in the United States following Perrigo's receipt of all necessary regulatory approvals.